Navidea Biopharmaceuticals Investor Relations Material
Latest events
EGM 2024
Navidea Biopharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Navidea Biopharmaceuticals Inc
Access all reports
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing precision immunodiagnostic agents and immunotherapeutics. Its primary technology platform, Manocept, is designed to target the CD206 receptor found on activated macrophages, which plays a key role in diagnosing and treating diseases such as cancer, autoimmune conditions, and inflammatory diseases. The company operates through two main segments: Diagnostic Substances, which include imaging agents, and Therapeutic Development Programs, aimed at therapeutic applications of its platform. Navidea is headquartered in Dublin, Ohio, and its shares are traded on the OTC Markets.
Latest articles
Master of Tickets: Breaking Down Live Nation Entertainment
Since merging in 2010, Ticketmaster and Live Nation have built an expansive ecosystem that dominates global live entertainment.
6 Dec 2024
Peter Beck: The Innovator at Rocket Lab
Peter Beck, born and raised in New Zealand, is one of the key individuals in the aerospace industry as the founder and CEO of Rocket Lab.
6 Dec 2024
Prada: The Story of an Icon
Prada's journey from a small Milan boutique to a global luxury empire, led by Miuccia's innovation and creativity.
5 Dec 2024
Ticker symbol
NAVB
Country
🇺🇸 United States